Following U.S. Stocks were among the “Top Losers” during Friday’s trade: Halcon Resources Corp (NYSE:HK), Royal Gold, Inc USA) (NASDAQ:RGLD), Curis, Inc (NASDAQ:CRIS), CollabRx Inc(NASDAQ:CLRX)
Their insights are depicted underneath:
Halcon Resources Corp (NYSE:HK)’s shares dwindled -9.23%, and closed at $1.77.
According to GLOBE NEWSWIRE, On February 25, Halcón Resources Corporation (HK), declared its fourth quarter and full year 2014 results.
Halcon generated total proceeds of $239.5 million for the quarter ended December 31, 2014. Proceeds for the full year 2014 totaled $1,148.3 million, an raise of 15% contrast to the full year 2013.
Production for the three months and full year ended December 31, 2014 was 46,076 barrels of oil equivalent per day (Boe/d) and 42,107 Boe/d, respectively. The Corporation stated full year 2014 production above its guidance range. Production was comprised of 81% oil, 9% natural gas liquids (NGLs) and 10% natural gas for the quarter and 83% oil, 7% NGLs and 10% natural gas for the year.
Counting the influence of hedges, Halcon realized 105% of the average NYMEX oil price, 35% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price during the fourth quarter 2014. For the full year 2014, counting the influence of hedges, the Corporation realized 91% of the average NYMEX oil price, 36% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price.
Total operating costs per unit, after adjusting for selected items, reduced by 23% to $21.27 per Boe during the three months ended December 31, 2014, contrast to the same period of 2013. Total operating costs per unit for the full year, after adjusting for selected items, were $24.14 per Boe, representing a decrease of 17% as compared to 2013.
After adjusting for selected items primarily related to the non-cash influence of derivatives and non-cash impairment charges, net revenue was $20.6 million, or $0.05 per diluted share, and $71.7 million, or $0.17 per diluted share, for the quarter and full year ended December 31, 2014, respectively. Halcon stated net revenue accessible to ordinary stockholders of $247.3 million, or $0.48 per diluted share for the fourth quarter and $282.9 million, or $0.59 per diluted share for the year.
Halcon Resources Corporation is an independent energy corporation engaged in the attainment, production, exploration and development of onshore oil and natural gas properties in the United States.
Royal Gold, Inc USA) (NASDAQ:RGLD) declined -8.86%, and closed at $63.03. The stock has the beta value of 0.19, and its volatility for the week is 3.63%, while for the month it is 2.64%. The company has the market capitalization of $8.73M. The mean recommendation of analysts for this stock is 2.20.(where 1=Buy, 5=Sale).
Royal Gold, Inc., together with its auxiliaries, attains and manages precious metals royalties, metal streams, and similar interests. It focuses on acquiring royalty interests or to finance projects that are in production or in development stage in exchange for royalty interests.
Curis, Inc (NASDAQ:CRIS) dipped -8.71%, and closed at $3.04.
According to GLOBE NEWSWIRE, Curis, Inc. (CRIS), a biotechnology corporation focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, declared that Dr. Mani Mohindru, Vice President, Corporate Strategy and Investor Relations, will present at the 27th Annual Roth Conference on Tuesday, March 10, 2015, at 12:00 p.m. Pacific Time in Dana Point, CA.
Curis is a biotechnology corporation focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’ pipeline of drug candidates comprises CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor.
CollabRx Inc(NASDAQ:CLRX) dipped -8.00%, and closed at $1.15.
According to Globenewswire, CollabRx, Inc. (CLRX), declared the closing of its formerly declared underwritten public offering of 2,362,205 shares of its ordinary stock at an offering price of $1.27 per ordinary share. In addition, the underwriter exercised the over-allotment option to purchase an additional 354,330 shares. Gross proceeds to CollabRx from this offering are about $3,450,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by CollabRx.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
